Navigation Links
SPO Medical to Conduct Live Investor Meeting on April 29, 2008
Date:4/10/2008

Using WallStreet VIPs' New Platform to Reach Wide Investor Audience

SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced today that it will be delivering a live, virtual investor presentation, using WallStreet VIPs' new platform on April 29, 2008 at 1 PM Eastern Daylight Time (EDT).

NEW YORK, April 10 /PRNewswire-FirstCall/ -- "SPO Medical is a company on the move, though many investors still are not familiar with us," said Michael Braunold, President and Chief Executive Officer of SPO Medical. "We just reported our 2007 full year results with record sales; we added two new professional products, the finger PulseOx 6000(TM) and the hand-held PulseOx 6100(TM), and increased our network of distributors to 38 countries. Using WallStreet VIPs, we disseminate our story to the investor community broadcasting directly on the internet. It's a very effective way to reach out to the broader investor community, since presenters and investors can meet easily and conveniently from their respective offices."

"WallStreet VIPs is a 21st century productivity solution to the challenges of scheduling quality time for live meetings and provide great value added for every public company's comprehensive Investor Relations strategy in today's global village and permanent time constraints," stated Jerry Cahn, Ph.D., J.D., President of WallStreet VIPs. "Investor meetings are the life-blood of public companies. They enable the companies to maintain contact with the investor community educating and updating them on the company's business strategy and developments. CEOs traditionally engage in road shows traveling from city-to-city to meet investors impacting their time and attention that should be devoted to running their businesses."

For a free invitation to SPO Medical's virtual meeting, please register at http://www.WallStreetVIPs.com

About SPO Medical

SPO Medical (SPOM) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spomedical.com.

About Wall Street VIPs

WallStreet VIPs is the 21st century productivity solution to the challenges of scheduling quality time, live meetings with potential and existing investors. When integrated with face-to-face meetings for the most serious investors making commitments, VIPs become a key part of every company's comprehensive investor relations strategy. WallStreet VIPs coordinates the whole program, scheduling the event, inviting qualified investors, coaching the presenter on using the platform, helping make the investor presentation compelling and providing details on the attending audience. For details, see: http://www.WallStreetVIPs.com.

Safe Harbor:

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, the introduction of competing products, market acceptance of our new products, changes in our operating strategy or development plans and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007. We undertake no obligation to revise or update any forward-looking statement for any reason.

Investor Contacts

SPO Medical: Target 3 Communications:

Michael Braunold, President & CEO Eugene Feyman, Director

info@spomedical.com eugene@target3.com

+1-805-823-8163 +1-646-827-0009


'/>"/>
SOURCE SPO Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... UCHealth ( Aurora, Colorado ) ... nodule patient management. In addition to optimizing care coordination ... the lung, UCHealth looks to improve provider workflow by ... Stephanie Brown, RN , Thoracic Nurse Navigator, ... an Excel spreadsheet, which was extremely arduous and susceptible ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017  Windtree ... biotechnology company focusing on developing aerosolized KL4 surfactant ... from a preclinical influenza study showed that aerosolized ... survival in a well-established preclinical animal model. The ... a growing body of evidence that supports the ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search ... Commercial Officer with GenePeeks. Matt is a veteran life sciences and molecular ... genomics company focused on identifying inherited disease risk in future generations. In his ...
(Date:2/15/2017)... 15, 2017  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the fourth quarter and full year ended December ... year for Vanda as we continued to demonstrate ... long-term exclusivity for Fanapt," said Mihael H. Polymeropoulos, ... emerging pipeline with important 2017 milestones underscores Vanda,s ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the LEERINK Partners 6th ... Palace Hotel on Wednesday, February 15, 2017 at 10 ... of the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
Breaking Biology News(10 mins):